RadarScope: MRK — Analiza Fundamentala

Market Cap

$378.0B

P/E Ratio

121.4

Profit Margin

4.8%

ROE

6.6%

📈 Earnings Report — 2026-08

Ultimul trimestru raportat

EPS Actual

$-0.13

▲ 89.8% QoQ▼ 106.1% YoY

EPS Estimat

$-0.27049

Beat by 51.9%

Revenue Actual

$16.61B

▲ 2.0% QoQ▲ 5.1% YoY

Revenue Estimat

$16.37B

Beat by 1.5%

Istoric Ultimele 4 Trimestre

2026-08

EPS Actual

$-0.13

EPS Est.

$-0.27049

Revenue

$16.61B

Beat/Miss

Beat by 51.9%

2026-04

EPS Actual

$-1.28

EPS Est.

$-1.47

Revenue

$16.29B

Beat/Miss

Beat by 12.9%

2026-02

EPS Actual

$2.04

EPS Est.

$2.01

Revenue

$16.40B

Beat/Miss

Beat by 1.5%

2025-10

EPS Actual

$2.58

EPS Est.

$2.36

Revenue

$17.28B

Beat/Miss

Beat by 9.3%

Urmatorul Raport

Data

2026-10-29

EPS Estimat

$2.22

Revenue Estimat

$17.31B

💰 Dividende Recente

2026-09

$0.85

Yield: 2.22%

Plata: 2026-10

2026-06

$0.85

Yield: 2.92%

Plata: 2026-07

2026-03

$0.85

Yield: 2.88%

Plata: 2026-04

2025-12

$0.85

Yield: 3.27%

Plata: 2026-01

📊 Scoruri Companie

Crestere 9/10

Revenue & Profit Growth

Evaluare 2/10

P/E · P/B · P/S

Calitate 7/10

Marje · ROE · Datorii

Risc 3/10

Beta · Market Cap

📈 Date Financiare Istorice in miliarde USD

💰 Revenue

📊 Net Profit

💵 Cash Flow

Operating (albastru) · Free (violet)

🏦 Cash & Datorii

Cash (verde) · Long-term Debt (rosu)

💸 Operating Expenses

🤖 Analiza RadarScope AI

Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.

💡 Disponibil pe Trader / Elite

🐂 BULL CASE

Disponibil pe Trader / Elite

🐻 BEAR CASE

Disponibil pe Trader / Elite

TINE Upgrade la Trader sau Elite pentru verdictul AI.

📖 Indicatorii lui Lynch — concluzii rapide dupa Peter Lynch

PEG — P/E in contextul cresterii

SCUMP

PEG 5.72 · cu dividend 5.18 · crestere EPS ~21.2%/an. Regula Lynch: ~1 corect, sub 0.5 foarte atractiv, peste 2 scump.

P/E vs istoria proprie si sectorul

P/E acum 121.4.
vs media proprie 5 ani (168.4): SUB media sa
vs sector Healthcare (22.7): PESTE sector
Lynch: compara P/E cu propria istorie si media industriei, nu in absolut.

Procentul din vanzari (concentrare produs)

CONCENTRAT PE 1 PRODUS

Pharmaceutical segment 89% · Animal Health segment 10% · Other Segments 1%
Lynch: un produs genial care aduce sub ~10% din venituri nu misca actiunea.

Cash si datorie

DATORIE NETA

Datorie neta pe actiune $14.20 (mai multa datorie decat cash).
Datorie/Capital 1.29 DATORIE MARE — decide supravietuirea in vremuri grele (esential la ciclice si turnarounds).
Tip datorie: OK — TERMEN LUNG — majoritar pe termen lung (obligatiuni = timp de manevra). Scurt $2.9B / Lung $46.8B.

Marje de profit

MARJE SUBTIRI

Bruta 75.4% · Operationala 16.7% · Neta 4.8%. Marje mici — dar intr-o redresare de ciclu, tocmai firma cu marje mici are cea mai exploziva crestere procentuala a profitului.

Inventare vs vanzari

ATENTIE

Stocurile cresc mai repede ca vanzarile (inventar +9% vs vanzari +1%) — semnal de alarma clasic.

Povestea in 2 minute

De ce o detii: Analiza AI (verdict, bull case, bear case) este disponibila pe planurile Trader si Elite.
Ce trebuie sa mearga bine: Disponibil pe Trader / Elite
Obstacole: Disponibil pe Trader / Elite
Lynch: daca nu poti explica coerent in 2 minute de ce o detii, nu o intelegi.

🔬 Analiza Fundamentala Avansata · an fiscal 2025-12-31

🏦 Altman Z-Score

4.59 ZONA SIGURA

X1 Capital de lucru / Active	0.111	x1.2
X2 Profit reportat / Active	0.534	x1.4
X3 EBIT / Active	0.164	x3.3
X4 Capitalizare / Datorii	4.489	x0.6
X5 Vanzari / Active	0.475	x1.0

Praguri Altman (1968): >2,99 sigur · 1,81–2,99 gri · <1,81 pericol de faliment

💪 Piotroski F-Score

4/9 SLAB

✓ROA pozitiv13.34%

✓Cash flow operational pozitiv16.47B

✗ROA in crestere13.34% vs 14.62%

✗Cash flow > Profit net (calitate)16.47B vs 18.25B

✗Datorie pe termen lung in scadere34.2% vs 29.4% din active

✓Lichiditate curenta in crestere1.54 vs 1.36

✓Fara emisiune de actiuni noi2474.6M vs 2527.6M

✗Marja bruta in crestere74.8% vs 76.3%

✗Rotatia activelor in crestere0.47 vs 0.55

9 teste binare (Piotroski, 2000). 8–9 = putere financiara · 0–2 = slabiciune

⚖️ ROIC vs WACC

+17.23pp CREEAZA VALOARE

ROIC (randamentul capitalului)	22.25%
WACC (costul capitalului)	5.02%

Ipoteze (la vedere):
Rata fara risc 4.2% (USD) · Beta 0.21 · Prima de risc 5.5%
Cost capitaluri proprii 5.36% · Cost datorie 2.75% · Impozit efectiv 13.3%

Metode publice: Altman, E. (1968), Journal of Finance · Piotroski, J. (2000), Journal of Accounting Research · ROIC/WACC prin CAPM. Fiecare cifra isi arata componentele si pragurile — poti reface calculul manual.

📊 Metrici Fundamentale

P/E TTM121.4

P/B TTM9.02

P/S TTM5.69

EV/EBITDA30.7

Gross Margin75.4%

Operating Margin16.7%

Net Margin4.8%

ROE6.6%

ROA2.4%

Debt/Equity1.29

Current Ratio1.32

FCF Yield4.2%

Dividend Yield2.20%

Beta0.21

💰 Venituri & Profit (ultimele trimestre)

Trimestru	Revenue	Gross Profit	Net Income	EPS
2026-06	$16.6B	$12.2B	$-1.3B	$-0.54
2026-03	$16.3B	$13.3B	$-4.2B	$-1.72
2025-12	$16.3B	$11.5B	$3.0B	$1.20
2025-09	$17.2B	$13.0B	$5.8B	$2.32

🏢 Profil Companie

CEORobert Davis

Angajati74000

IPO1978-01-13

Websitehttps://www.merck.com...

52W High$154.49

52W Low$77.58

Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhil...

🎯 Score Breakdown

Calitate Companie (Q) 7/10

Risc Speculativ (R) 3/10

Scor AI RadarScope 0/100

VERDICT FINAL

TINE

Upgrade la Trader sau Elite pentru verdictul AI.

🔒 Analiza completa disponibila cu cont SignalRadar